drugset / Trial / NCT00072098

Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer

NCT00072098

Phase 1 Terminated 22 enrolled Max Sung National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.

Timeline

Start
2003-09
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject interleukin-12 Protein / enzyme biologic Other
Background adenovirus vector Unknown Other